First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors (Q36021635)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

title

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

author

Linda T Vahdat

series ordinal

6

object named as

Linda T Vahdat

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

author name string

Alexander N Starodub

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Allyson J Ocean

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Manish A Shah

series ordinal

3

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Michael J Guarino

series ordinal

4

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Vincent J Picozzi

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Sajeve S Thomas

series ordinal

7

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Serengulam V Govindan

series ordinal

8

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Pius P Maliakal

series ordinal

9

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

William A Wegener

series ordinal

10

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Steven A Hamburger

series ordinal

11

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

Robert M Sharkey

series ordinal

12

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

David M Goldenberg

series ordinal

13

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

language of work or name

English

0 references

publication date

5 May 2015

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

published in

Clinical Cancer Research

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

volume

21

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

issue

17

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

page(s)

3870-3878

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

cites work

Trop-2 is a determinant of breast cancer survival

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Antibody-drug conjugates in cancer therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Upregulation of Trop-2 quantitatively stimulates human cancer growth

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Trop2: a possible therapeutic target for late stage epithelial carcinomas

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

2 October 2017

Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

11 July 2018

Brentuximab vedotin.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

23 September 2018

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

retrieved

23 September 2018

Letter to the Editor: Efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309–1

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25944802

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25944802

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1158/1078-0432.CCR-14-3321

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

PMC publication ID

4558321

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

PubMed publication ID

25944802

1 reference

stated in

Europe PubMed Central

PMC publication ID

4558321

retrieved

11 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36021635&oldid=1987523377"